×
About 10,418 results

ALLMedicine™ Lupus Nephritis Center

Research & Reviews  4,913 results

Association of antiphospholipid antibodies with clinical activity and renal pathologica...
https://doi.org/10.1177/09612033211006781
Lupus Zhang J, Zhang J et. al.

Apr 9th, 2021 - This study aimed to investigate the association of antiphospholipid antibodies (aPL) with clinical activity and renal pathological activity in patients with lupus nephritis (LN). Levels of anticardiolipin () antibodies, anti-β2-glycoprotein I (ant...

Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupu...
https://doi.org/10.1080/1354750X.2021.1910343
Biomarkers : Biochemical Indicators of Exposure, Response... Burcsar S, Toldi G et. al.

Apr 7th, 2021 - There is a lack of noninvasive biomarkers to identify lupus nephritis (LN). Soluble urokinase plasminogen activator receptor (suPAR) is a sensitive biomarker of ongoing inflammation and a potential marker of podocyte dysfunction. The aim of this s...

LONG TERM RENAL SURVIVAL OF PEDIATRIC PATIENTS WITH LUPUS NEPHRITIS.
https://doi.org/10.1093/ndt/gfab152
Nephrology, Dialysis, Transplantation : Official Publicat... Demir S, Gülhan B et. al.

Apr 7th, 2021 - Childhood-onset systemic lupus erythematosus (SLE) is more severe than adult-onset disease, including more frequent kidney involvement. This study aimed to investigate baseline clinical features, treatment modalities, short- and long-term renal ou...

Inhibitory effect of anti-malarial agents on the expression of proinflammatory chemokin...
https://doi.org/10.1080/0886022X.2021.1908901
Renal Failure; Sato R, Imaizumi T et. al.

Apr 6th, 2021 - Although anti-malarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ) are currently used for the treatment of systemic lupus erythematosus, their efficacy for lupus nephritis (LN) remains unclear. Given that upregulation of glomerular Toll-...

Predictors of renal flares and long-term renal outcome in patients with lupus nephritis...
https://www.ncbi.nlm.nih.gov/pubmed/33822705
Clinical and Experimental Rheumatology; Ligtenberg G, Arends S et. al.

Apr 6th, 2021 - To describe renal outcomes of the lupus nephritis (LN) population of the University Medical Centre Groningen (UMCG) in the Netherlands and to identify predictors for renal flares and long-term renal outcome in daily clinical practice. A retrospect...

see more →

Guidelines  11 results

Obinutuzumab Provides Two-Year Benefits for Lupus Nephritis
https://www.hcplive.com/view/obinutuzumab-two-year-benefits-lupus-nephritis

Nov 3rd, 2020 - After promising 18-month outcomes in patients with proliferative lupus nephritis, obinutuzumab showed sustained benefits through 2 years of treatment for patients burdened with the rheumatic disease.

Do Menopause and Aging Affect the Onset and Progression of Rheumatoid Arthritis and Systemic Lupus Erythematosus?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557711/
Cureus Shah L

Oct 11th, 2020 - Rheumatoid arthritis and systemic lupus erythematosus (SLE) are autoimmune diseases that are commonly seen in the female population. Rheumatoid arthritis mainly consists of distal symmetrical deforming polyarthritis. SLE patients have immune compl...

Revision of the International Society of Nephrology/Renal Pathology Society classificat...
https://doi.org/10.1016/j.kint.2017.11.023
Kidney International; Bajema IM, Wilhelmus S et. al.

Feb 20th, 2018 - We present a consensus report pertaining to the improved clarity of definitions and classification of glomerular lesions in lupus nephritis that derived from a meeting of 18 members of an international nephropathology working group in Leiden, Neth...

Overview of lupus nephritis management guidelines and perspective from Asia.
https://doi.org/10.1111/1756-185X.12212
International Journal of Rheumatic Diseases; Mok CC, Yap DY et. al.

Jan 2nd, 2014 - Lupus nephritis (LN) is a common and important manifestation of systemic lupus erythematosus (SLE). Evidence suggests higher rates of lupus renal involvement in Asian populations, and maybe more severe nephritis, compared with other racial or ethn...

Joint European League Against Rheumatism and European Renal Association-European Dialys...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465859
Annals of the Rheumatic Diseases; Bertsias GK, Tektonidou M et. al.

Aug 1st, 2012 - To develop recommendations for the management of adult and paediatric lupus nephritis (LN). The available evidence was systematically reviewed using the PubMed database. A modified Delphi method was used to compile questions, elicit expert opinion...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  5,141 results

Association of antiphospholipid antibodies with clinical activity and renal pathologica...
https://doi.org/10.1177/09612033211006781
Lupus Zhang J, Zhang J et. al.

Apr 9th, 2021 - This study aimed to investigate the association of antiphospholipid antibodies (aPL) with clinical activity and renal pathological activity in patients with lupus nephritis (LN). Levels of anticardiolipin () antibodies, anti-β2-glycoprotein I (ant...

Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupu...
https://doi.org/10.1080/1354750X.2021.1910343
Biomarkers : Biochemical Indicators of Exposure, Response... Burcsar S, Toldi G et. al.

Apr 7th, 2021 - There is a lack of noninvasive biomarkers to identify lupus nephritis (LN). Soluble urokinase plasminogen activator receptor (suPAR) is a sensitive biomarker of ongoing inflammation and a potential marker of podocyte dysfunction. The aim of this s...

LONG TERM RENAL SURVIVAL OF PEDIATRIC PATIENTS WITH LUPUS NEPHRITIS.
https://doi.org/10.1093/ndt/gfab152
Nephrology, Dialysis, Transplantation : Official Publicat... Demir S, Gülhan B et. al.

Apr 7th, 2021 - Childhood-onset systemic lupus erythematosus (SLE) is more severe than adult-onset disease, including more frequent kidney involvement. This study aimed to investigate baseline clinical features, treatment modalities, short- and long-term renal ou...

Inhibitory effect of anti-malarial agents on the expression of proinflammatory chemokin...
https://doi.org/10.1080/0886022X.2021.1908901
Renal Failure; Sato R, Imaizumi T et. al.

Apr 6th, 2021 - Although anti-malarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ) are currently used for the treatment of systemic lupus erythematosus, their efficacy for lupus nephritis (LN) remains unclear. Given that upregulation of glomerular Toll-...

Predictors of renal flares and long-term renal outcome in patients with lupus nephritis...
https://www.ncbi.nlm.nih.gov/pubmed/33822705
Clinical and Experimental Rheumatology; Ligtenberg G, Arends S et. al.

Apr 6th, 2021 - To describe renal outcomes of the lupus nephritis (LN) population of the University Medical Centre Groningen (UMCG) in the Netherlands and to identify predictors for renal flares and long-term renal outcome in daily clinical practice. A retrospect...

see more →

News  343 results

FDA Approves Voclosporin for Lupus Nephritis
https://www.medscape.com/viewarticle/944794

Jan 26th, 2021 - The Food and Drug Administration has approved voclosporin (Lupkynis) for the treatment of lupus nephritis, according to a Jan. 22 press release from manufacturer Aurinia Pharmaceuticals. Lupkynis is a calcineurin-inhibitor immunosuppressant, and i...

FDA Expands Belimumab Indication to Adults With Lupus Nephritis
https://www.medscape.com/viewarticle/942894

Dec 17th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for belimumab (Benlysta) to adults with active lupus nephritis who are receiving standard therapy. Roughly 40% of patients with systemic lupus erythematosus (SLE) develop lupus ...

A 27-Year-Old Woman With Knee Pain and Facial Rash: Osmosis USMLE Study Question
https://www.medscape.com/viewarticle/891226_2

Nov 12th, 2020 - This patient has characteristic symptoms of systemic lupus erythematosus (SLE), namely a "butterfly" rash over the bridge of her nose and cheeks, as well as arthritis, and fatigue. However, she also has hypertension, peripheral edema, and an abnor...

Obinutuzumab Provides Two-Year Benefits for Lupus Nephritis
https://www.hcplive.com/view/obinutuzumab-two-year-benefits-lupus-nephritis

Nov 3rd, 2020 - After promising 18-month outcomes in patients with proliferative lupus nephritis, obinutuzumab showed sustained benefits through 2 years of treatment for patients burdened with the rheumatic disease.

Do Menopause and Aging Affect the Onset and Progression of Rheumatoid Arthritis and Systemic Lupus Erythematosus?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557711/
Cureus Shah L

Oct 11th, 2020 - Rheumatoid arthritis and systemic lupus erythematosus (SLE) are autoimmune diseases that are commonly seen in the female population. Rheumatoid arthritis mainly consists of distal symmetrical deforming polyarthritis. SLE patients have immune compl...

see more →

Patient Education  7 results see all →